Another Drug Approved For Alopecia Areata: Litfulo Ritlecitinib

In June 2023, the US FDA approved its second oral drug against alopecia areata, ritlecitinib. This kinase inhibitor blocks JAK 3 and tyrosine kinase which creates a therapeutic effect on auto-immune disorders. The drug will be branded as Litfulo and is intended to treat severe alopecia areata in people above the age of 12. Eli Lilly’s Olumiant, which became the first approved oral drug for AA back in June 2022, is only approved for adults.